- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 88,010 | 13.06.24 15:15:52 | -1,310 | -1,47% | 87,670 | 87,720 | 89,300 | 89,320 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 956,000 | 13.06.24 14:35:44 | +19,800 | +2,11% | 938,200 | 949,800 | 947,200 | 936,200 |
